T. Rowe Price Associates
EVMN

T. Rowe Price Associates’s Evommune Inc EVMN Stock Holding History

T. Rowe Price Associates’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.7M Buy
1,119,021
+336,900
+43% +$7.62M ﹤0.01% 979
2025
Q4 		$13.4M Buy
+782,121
New +$14.7M ﹤0.01% 1171

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $1.02B AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

T. Rowe Price Associates's EVMN Position: Q1 2026 in Review

T. Rowe Price Associates increased its Evommune Inc (EVMN) stake by 43% in Q1 2026, buying an estimated $7.62M and bringing the position to 1,119,021 shares worth $25.7M. The position accounts for ﹤0.01% of the portfolio, ranked #979.

T. Rowe Price Associates first reported a position in EVMN in Q4 2025 and has held it in 2 quarters since. 84 funds tracked by Wall St. Rank hold EVMN as of Q1 2026.

  • T. Rowe Price Associates held 1,119,021 shares of Evommune Inc worth $25.7M as of Q1 2026.
  • T. Rowe Price Associates bought 336,900 Evommune Inc shares in Q1 2026, an estimated $7.62M.
  • Evommune Inc made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #979 holding.
  • T. Rowe Price Associates first reported a position in Evommune Inc in Q4 2025 and has held it in 2 quarters since.
  • 84 funds tracked by Wall St. Rank held Evommune Inc as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.